Trial Profile
Effects of Indacaterol in Symptomatic COPD Patients With Low Risk of Exacerbations
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jul 2017
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Salbutamol
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Novartis
- 11 Aug 2016 Status changed from recruiting to completed.
- 06 Apr 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 21 Apr 2015 New trial record